Of ends and means

American Journal of Transplantation

Volumn 6, Issue 10, 2006, Pages 2228-2229

  Kirk, A D ^a   Light, J A ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; TACROLIMUS;

EDITORIAL; GRAFT FAILURE; HEALTH CARE ORGANIZATION; HEALTH CENTER; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MORBIDITY; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; UNITED STATES; WEANING;

EID: 33748517654     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01500.x     Document Type: Editorial

References (13)

1. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. 2005. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
2. Calne R, Moffatt SD, Friend PJ et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-1616.
3. Knechtle SJ, Fernandez LA, Pirsch JD et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754-760.
4. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-long-term results. Am J Transplant 2005; 5: 2539-2548.
5. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465-474.
6. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87-92.
7. Tan H, Kaczorowski D, Basu A et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37: 4235-4240.
8. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-515.
9. Torrealba JR, Fernandez LA, Kanmaz T, Oberley TD et al. Immunotoxin-treated rhesus monkeys: A model for renal allograft chronic rejection. Transplantation 2003; 76: 524-530.
10. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 2005; 80: 1194-1197.
11. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. http://ohsr.od.nih.gov/guidelines/belmont.html.
12. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects-2004. http://www.wma.net/e/policy/b3. htm.
13. Code of Federal Regulations, Title 45, Public Welfare, Department of Health and Human Services, Part 46, Protection of Human Subjects: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm.